I’ve got some bad news and not-so-bad news. The bad news is that it is correct that these monoclonal antibodies and convalescent plasma will not provide a meaningful benefit to the novel strains. The not-so-bad news is that this is not a departure from the status quo since these treatments really don’t work for our current stains. The data to support monoclonals is very week (especially in hospitalized patients who may be harmed), and the RECOVERY Trial just halted enrollment in the convalescent plasma arm after the planned interim analysis showed no benefit.
Some good news is that the current crop of mRNA vaccines will likely provide protection against severe disease from all of these strains. Protection against mild or asymmetric disease, or actually preventing infection is unknown.